140 related articles for article (PubMed ID: 34702119)
21. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study.
Reiser M; Borte M; Huscher D; Baumann U; Pittrow D; Sommer C; Stangel M; Fasshauer M; Gold R; Hensel M
Eur J Haematol; 2017 Aug; 99(2):169-177. PubMed ID: 28467615
[TBL] [Abstract][Full Text] [Related]
22. Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy.
McQuilten ZK; Weinkove R; Thao LTP; Crispin P; Degelia A; Dendle C; Gilbertson M; Johnston A; Keegan A; Pepperell D; Pullon H; Reynolds J; van Tonder T; Trotman J; Waters N; Wellard C; Weston H; Morrissey CO; Wood EM
Blood Adv; 2024 Apr; 8(7):1787-1795. PubMed ID: 38592710
[TBL] [Abstract][Full Text] [Related]
23. A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis.
Hémar V; Rivière E; Greib C; Machelart I; Roucoules M; Prot C; Pellegrin JL; Viallard JF; Lazaro E
Immunotherapy; 2021 Dec; 13(18):1491-1499. PubMed ID: 34743547
[TBL] [Abstract][Full Text] [Related]
24. Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives.
Ar MC; El Fakih R; Gabbassova S; Alhuraiji A; Nasr F; Alsaeed A; Sayinalp N; Marashi M
Leuk Res; 2023 Oct; 133():107365. PubMed ID: 37643508
[TBL] [Abstract][Full Text] [Related]
25. Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management.
Sánchez-Ramón S; Bermúdez A; González-Granado LI; Rodríguez-Gallego C; Sastre A; Soler-Palacín P;
Front Immunol; 2019; 10():586. PubMed ID: 30984175
[No Abstract] [Full Text] [Related]
26. High Rates of Community and Hospital Acquired Infections in Patients with Cellular Immunodeficiencies.
Hanisch BR; Davila Saldana BJ; Keller MD; Song X
J Clin Immunol; 2018 Oct; 38(7):804-809. PubMed ID: 30267241
[TBL] [Abstract][Full Text] [Related]
27. Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.
Legendre P; Chahwan D; Marjanovic Z; Vignon M; Hermine O; Lortholary O; Morelle G; Darrodes M; Kahn JE; Ouzegdouh M; Chaibi P; Montestruc F; Caumont-Prim A; Le Jouan M; Hassani Y; Godeau B; Durand-Zaleski I; Mouthon L
Clin Immunol; 2020 Jun; 215():108419. PubMed ID: 32289463
[TBL] [Abstract][Full Text] [Related]
28. [Clinical features of children with immunodeficiency and
Wang WP; Liu QB
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Dec; 22(12):1300-1305. PubMed ID: 33328001
[TBL] [Abstract][Full Text] [Related]
29. Genetic predisposition and hematopoietic malignancies in children: Primary immunodeficiency.
van der Werff Ten Bosch J; van den Akker M
Eur J Med Genet; 2016 Dec; 59(12):647-653. PubMed ID: 26975585
[TBL] [Abstract][Full Text] [Related]
30. Immunodeficiency risk score for prediction of mortality by parainfluenza virus infection in patients with hematologic malignancy.
Lee J; Jung J; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Choi EJ; Park HS; Lee JH; Lee JH; Lee KH; Kim SH
Ann Hematol; 2020 Jun; 99(6):1231-1239. PubMed ID: 32382770
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy.
Windegger TM; English J; Weston H; Morwood K; Kynn M; Scuffham P; Fung YL
Asia Pac J Clin Oncol; 2021 Dec; 17(6):546-554. PubMed ID: 33460509
[TBL] [Abstract][Full Text] [Related]
32. Secondary immunodeficiency in lymphoproliferative malignancies.
Friman V; Winqvist O; Blimark C; Langerbeins P; Chapel H; Dhalla F
Hematol Oncol; 2016 Sep; 34(3):121-32. PubMed ID: 27402426
[TBL] [Abstract][Full Text] [Related]
33. Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China.
Ye C; Chen W; Gao Q; Chen Y; Song X; Zheng S; Liu J
Med Sci Monit; 2021 Jul; 27():e930241. PubMed ID: 34238914
[TBL] [Abstract][Full Text] [Related]
34. Access and use of immunoglobulins in supportive cancer care: A thematic analysis of a systematic review data set.
Counihan M; Cervenakova L; Misztela D; Van Baelen M; D Naughton B
J Med Access; 2024; 8():27550834241236596. PubMed ID: 38559466
[TBL] [Abstract][Full Text] [Related]
35. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.
Agostini C; Blau IW; Kimby E; Plesner T
Expert Rev Clin Immunol; 2016 Sep; 12(9):921-6. PubMed ID: 27415820
[TBL] [Abstract][Full Text] [Related]
37. Secondary antibody deficiency.
Duraisingham SS; Buckland MS; Grigoriadou S; Longhurst HJ
Expert Rev Clin Immunol; 2014 May; 10(5):583-91. PubMed ID: 24684706
[TBL] [Abstract][Full Text] [Related]
38. Infections in hematological malignancies.
Khayr W; Haddad RY; Noor SA
Dis Mon; 2012 Apr; 58(4):239-49. PubMed ID: 22449371
[No Abstract] [Full Text] [Related]
39. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.
Patel V; Cowan J
Expert Rev Clin Immunol; 2020 Jul; 16(7):711-716. PubMed ID: 32588670
[TBL] [Abstract][Full Text] [Related]
40. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.
Ferrari S; Caprioli C; Weber A; Rambaldi A; Lussana F
Leuk Lymphoma; 2021 Jun; 62(6):1490-1496. PubMed ID: 33461387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
